Impact of integrated upper limb spasticity management including botulinum toxin A on patient centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS III)
Objectives Describe the rationale and protocol for the Upper Limb International Spasticity (ULIS) III study, which aims to evaluate the impact of integrated spasticity management, involving multiple botulinum toxin A (BoNT A) injection cycles and concomitant therapies, on patient centred goal attainment. Outline novel outcome assessment methods for ULIS III and report initial evaluation data from goal setting in early stages of the study. Design Large international longitudinal cohort study of integrated upper limb spasticity management, including BoNT A. Participants and setting ULIS III is a 2 year study expected to enrol >1000 participants at 58 study centres across 14 countries. Interventions The study design is non interventional and intended to reflect real life clinical practice. It will describe injection practices and additional treatment strategies, and record clinical decision making in a serial approach to long term spasticity management. Outcome measures ULIS III will use a goal directed approach to selection of targeted standardised measures to capture the diversity of presentation, goals and outcomes. ULIS III will implement the Upper Limb Spasticity Index, a battery of assessments including a structured approach to goal attainment scaling (Goal Attainment Scaling Evaluation of Outcomes for Upper Limb Spasticity tool) alongside a limited set of standardised measures, chosen according to patients' selected goal areas. Concomitant therapy inputs, patient satisfaction with engagement in goal setting, health economic end points and health related quality of life data will also be captured. Results of initial evaluation of goal quality Recruitment started in January 2015. By June 2015, 58 sites had been identified and initial data collected for 79 patients across 13 sites in 3 countries. Goal setting data were quality checked and centres rated on the basis of function related and Specific, Measurable, Achievable, Realistic, Timed (SMART) characteristics of goal statements. Overall, 11/13 centres achieved the highest rating (A+ Conclusions ULIS III will provide valuable information regarding treatment of and outcomes from real life upper limb spasticity management worldwide. Trial registration number NCT02454803; Pre results.
BMJ Open